• Partial BACE Inhibition and Synaptic Transmission

  2026-08-14

  Satir et al. show that partial β-secretase inhibition can reduce amyloid β secretion by up to approximately 50% without impairing synaptic transmission in cultured primary cortical neurons. The study defines a potential exposure window for BACE inhibitor development while emphasizing that stronger inhibition may compromise neuronal function.

• Validated HPLC Analysis of Trelagliptin Succinate

  2026-08-14

  The reference study developed and validated a stability-indicating HPLC method that separates trelagliptin succinate from process-related and stress-generated impurities. By combining chromatographic validation with high-resolution tandem mass spectrometry, the work provides a practical quality-control framework for pharmaceutical dosage forms and related diabetes mellitus research workflows.

• Pioglitazone Workflows for PPARγ Research

  2026-08-13

  Build reproducible PPARγ activation assays across metabolic, macrophage, and neuroinflammation models with practical stock-preparation, dosing, and readout guidance. This workflow also translates recent STAT-1/STAT-6 macrophage findings into experiment-ready choices for inflammatory disease research.

• Berberine Hydrochloride: Applied Research Workflows

  2026-08-13

  Berberine hydrochloride connects AMPK-centered metabolic studies with practical LDLR, lipid, apoptosis, and oxidative-stress assays. This workflow-focused guide explains how to prepare the reagent, select model systems, translate cardiotoxicity findings responsibly, and troubleshoot the most common sources of variability.

• Quizartinib (AC220): From FLT3 Signal to Resistance

  2026-08-12

  Explore how Quizartinib (AC220) connects selective FLT3 inhibition with AML research, assay design, and resistance biology. This guide turns target engagement data into a more informative translational workflow.

• 2-Deoxy-D-glucose: Reproducible Assay Design

  2026-08-12

  Learn how 2-Deoxy-D-glucose (SKU B1027) can clarify glycolysis-dependent viability, proliferation, and cytotoxicity results through controlled dosing, formulation, and orthogonal readouts. This scenario-based guide separates product-supported parameters from workflow recommendations and highlights limitations when translating metabolic effects across cell models.

• Berberine hydrochloride: Reliable Cell Assays

  2026-08-11

  This scenario-driven guide shows how Berberine hydrochloride (SKU N1699) can improve experimental control in viability, proliferation, cytotoxicity, and mechanism-focused assays. It covers solubility, dosing, optical-readout controls, data interpretation, and practical vendor-selection criteria.

• CKI 7 dihydrochloride for Reliable Cell Assays

  2026-08-11

  This scenario-based guide explains how CKI 7 dihydrochloride, SKU B4936, can be incorporated into cell viability, proliferation, apoptosis, Wnt, circadian, and cancer biology workflows. It emphasizes mechanism-aware controls, solution handling, data interpretation, and practical reagent selection rather than treating pathway inhibition as a standalone cytotoxicity readout.

• Chlorpromazine Workflows for Neural and Liver Models

  2026-08-10

  Chlorpromazine hydrochloride supports controlled dopamine receptor signaling, antiemetic, and schizophrenia research while also serving as a pharmacological comparator in hepatic nanoparticle assays. This workflow connects receptor-focused experiments with cell-resolved nanoparticle uptake without overstating what either model can prove.

• GSK621: Reliable AMPK Assay Workflows

  2026-08-09

  Learn how GSK621 (SKU B6020) can strengthen AMPK-centered viability, proliferation, cytotoxicity, and immunometabolic assays. This scenario-based guide covers formulation, controls, readout interpretation, AML applications, and practical product-selection criteria.

• MK 0893: Glucagon Receptor Antagonist Guide

  2026-08-08

  MK 0893 is a competitive, reversible glucagon receptor antagonist that blocks GCGR signaling through an extra-helical allosteric site. It shows nanomolar inhibition of receptor binding and cAMP signaling and reduces glucagon-driven hyperglycemia in humanized mouse and primate models.

• Anagliptin Vasorelaxation: Kv Channels and SERCA

  2026-08-07

  A 2025 Acta Diabetologica study identifies a direct vasorelaxant action of Anagliptin in phenylephrine-contracted rabbit aortic rings and links the response to voltage-dependent K+ channels and the SERCA pump. The findings extend evaluation of SK-0403 beyond glycemic pharmacology while defining important limits for interpretation in other vascular models.

• Thiamet G: An O-GlcNAcase Inhibitor for Disease Modeling

  2026-08-07

  Thiamet G is redefining how researchers modulate protein O-GlcNAcylation, enabling precision control in models of neurodegeneration, leukemia sensitization, and bone anabolism. This guide details applied workflows, troubleshooting strategies, and new mechanistic insights, empowering users to leverage Thiamet G for robust, reproducible results across cutting-edge disease models.

• Structure-Guided Proteomimetics Disrupt SARS-CoV-2 S-RBD/hAC

  2026-08-06

  This study presents a structure-guided approach to designing constrained proteomimetics that selectively inhibit the challenging SARS-CoV-2 Spike RBD/hACE2 protein–protein interaction. The work establishes new strategies for targeting complex viral-host interfaces, with implications for antiviral drug development and the broader field of PPI inhibitors.

• PRMT1-SRSF1 Axis Regulates Myocardial Hypertrophy via Methyl

  2026-08-06

  This study reveals that PRMT1 mitigates isoprenaline-induced myocardial hypertrophy by methylating SRSF1, thereby altering its phosphorylation state and functional role in cardiac cells. These findings advance understanding of protein methylation and selective splicing in cardiovascular pathology, highlighting new mechanistic links and potential therapeutic targets.

8228 records 11/549 page Previous Next First page 上5页 1112131415 下5页 Last page